ABBV 706
Alternative Names: ABBV-706Latest Information Update: 11 Aug 2025
At a glance
- Originator AbbVie
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 May 2025 Efficacy and adverse event data from a phase I trial in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 31 May 2024 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 May 2024 Efficacy and adverse events data from a phase I trial in Small cell lung cancer released by AbbVie